JMP Securities started coverage on shares of Inhibrx (NASDAQ:INBX) in a research note released on Tuesday morning, Price Targets.com reports. The firm issued a buy rating and a $46.00 target price on the stock.
Separately, Zacks Investment Research cut Inhibrx from a hold rating to a sell rating in a report on Friday, August 13th.
INBX opened at $36.77 on Tuesday. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.39 billion and a price-to-earnings ratio of -15.99. The company’s 50 day moving average is $30.73 and its 200 day moving average is $24.88. Inhibrx has a 12-month low of $14.27 and a 12-month high of $50.97.
A number of large investors have recently made changes to their positions in INBX. BlackRock Inc. increased its position in shares of Inhibrx by 21.1% in the first quarter. BlackRock Inc. now owns 599,708 shares of the company’s stock valued at $12,035,000 after buying an additional 104,676 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Inhibrx in the first quarter valued at approximately $2,821,000. New York State Common Retirement Fund increased its position in shares of Inhibrx by 55.3% in the first quarter. New York State Common Retirement Fund now owns 7,300 shares of the company’s stock valued at $147,000 after buying an additional 2,600 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Inhibrx by 0.6% in the first quarter. Geode Capital Management LLC now owns 150,470 shares of the company’s stock valued at $3,019,000 after buying an additional 920 shares in the last quarter. Finally, Platinum Investment Management Ltd. increased its position in shares of Inhibrx by 158.5% in the first quarter. Platinum Investment Management Ltd. now owns 155,401 shares of the company’s stock valued at $3,119,000 after buying an additional 95,296 shares in the last quarter. 51.67% of the stock is owned by institutional investors.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors.
Featured Article: Trade War
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.